251 related articles for article (PubMed ID: 17898787)
1. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
[TBL] [Abstract][Full Text] [Related]
2. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Qian Z; Zhang L; Cai Z; Sun L; Wang H; Yi Q; Wang M
Leuk Res; 2011 Mar; 35(3):380-6. PubMed ID: 21047686
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
12. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
14. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
15. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
16. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.
Prasad A; Shrivastava A; Papadopoulos E; Kuzontkoski PM; Reddy MV; Gillum AM; Kumar R; Reddy EP; Groopman JE
Clin Cancer Res; 2013 Jan; 19(1):85-95. PubMed ID: 23124440
[TBL] [Abstract][Full Text] [Related]
17. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
19. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]